These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides. Prakash TP; Kawasaki AM; Wancewicz EV; Shen L; Monia BP; Ross BS; Bhat B; Manoharan M J Med Chem; 2008 May; 51(9):2766-76. PubMed ID: 18399648 [TBL] [Abstract][Full Text] [Related]
3. 2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo. Prakash TP; Johnston JF; Graham MJ; Condon TP; Manoharan M Nucleic Acids Res; 2004; 32(2):828-33. PubMed ID: 14762210 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo. Shen L; Siwkowski A; Wancewicz EV; Lesnik E; Butler M; Witchell D; Vasquez G; Ross B; Acevedo O; Inamati G; Sasmor H; Manoharan M; Monia BP Antisense Nucleic Acid Drug Dev; 2003; 13(3):129-42. PubMed ID: 12954113 [TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides containing conformationally constrained 2',4'-(N-methoxy)aminomethylene and 2',4'-aminooxymethylene and 2'-O,4'-C-aminomethylene bridged nucleoside analogues show improved potency in animal models. Prakash TP; Siwkowski A; Allerson CR; Migawa MT; Lee S; Gaus HJ; Black C; Seth PP; Swayze EE; Bhat B J Med Chem; 2010 Feb; 53(4):1636-50. PubMed ID: 20108935 [TBL] [Abstract][Full Text] [Related]
6. Direct comparison of in vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA with that of 2'-O-(2-methoxy)ethyl-modified oligonucleotides. Koizumi M; Takagi-Sato M; Okuyama R; Araki K; Sun W; Nakai D; Tsutsumi S; Kawai K Oligonucleotides; 2006; 16(3):253-62. PubMed ID: 16978088 [TBL] [Abstract][Full Text] [Related]
7. In vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA in comparison of that of 2'-MOE-modified oligonucleotides. Koizumi M; Takagi-Sato M; Okuyama R; Araki K; Sun W; Nakai D Nucleic Acids Symp Ser (Oxf); 2007; (51):111-2. PubMed ID: 18029611 [TBL] [Abstract][Full Text] [Related]
8. Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. Seth PP; Siwkowski A; Allerson CR; Vasquez G; Lee S; Prakash TP; Wancewicz EV; Witchell D; Swayze EE J Med Chem; 2009 Jan; 52(1):10-3. PubMed ID: 19086780 [TBL] [Abstract][Full Text] [Related]
9. Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitro. Iwashita S; Shoji T; Koizumi M Methods Mol Biol; 2020; 2176():155-161. PubMed ID: 32865789 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice. Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955 [TBL] [Abstract][Full Text] [Related]
11. Chemical modification study of antisense gapmers. Stanton R; Sciabola S; Salatto C; Weng Y; Moshinsky D; Little J; Walters E; Kreeger J; DiMattia D; Chen T; Clark T; Liu M; Qian J; Roy M; Dullea R Nucleic Acid Ther; 2012 Oct; 22(5):344-59. PubMed ID: 22852836 [TBL] [Abstract][Full Text] [Related]
12. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Yu RZ; Lemonidis KM; Graham MJ; Matson JE; Crooke RM; Tribble DL; Wedel MK; Levin AA; Geary RS Biochem Pharmacol; 2009 Mar; 77(5):910-9. PubMed ID: 19056355 [TBL] [Abstract][Full Text] [Related]
15. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Hung G; Xiao X; Peralta R; Bhattacharjee G; Murray S; Norris D; Guo S; Monia BP Nucleic Acid Ther; 2013 Dec; 23(6):369-78. PubMed ID: 24161045 [TBL] [Abstract][Full Text] [Related]
16. RNA Reduction and Hepatotoxic Potential Caused by Non-Gapmer Antisense Oligonucleotides. Hori SI; Mitsuoka Y; Kugimiya A Nucleic Acid Ther; 2019 Feb; 29(1):44-50. PubMed ID: 30508397 [TBL] [Abstract][Full Text] [Related]
17. TricycloDNA-modified oligo-2'-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues--a comparative study of oligonucleotide length, design and chemistry. Murray S; Ittig D; Koller E; Berdeja A; Chappell A; Prakash TP; Norrbom M; Swayze EE; Leumann CJ; Seth PP Nucleic Acids Res; 2012 Jul; 40(13):6135-43. PubMed ID: 22467214 [TBL] [Abstract][Full Text] [Related]